Shanghai Cell Therapy Group Co., Ltd.

Dublin, May 11, 2023 /PRNewswire/ -- The "Global Stem Cell Partnering Terms and Agreements 2010-2023" report has been added to ResearchAndMarkets.com's offering. The Global Stem Cell Partnering Terms and Agreements 2010-2023 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in stem cell partnering Partnering agreement structure Partnering contract documents Top deals by value Most active dealmakers Average deal terms for stem cells The report provides a detailed understanding and analysis of how and why companies enter stem cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This report provides details of the latest stem cell agreements announced in the life sciences since 2010. The report takes the reader through a comprehensive review stem cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering stem cell partnering deals. The report presents financial deal term values for stem cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the stem cell partnering field; both the leading deal values and most active stem cell dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market. One of the key highlights of the report is that over 700 online deal records of actual stem cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. The initial chapters of this report provide an orientation of stem cell dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in stem cell dealmaking since 2010, including details of headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading stem cell deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in stem cell dealmaking with a brief summary followed by a comprehensive listing of stem cell deals announced by that company, as well as contract documents, where available. Chapter 5 provides a comprehensive and detailed review of stem cell partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of stem cell partnering deals signed and announced since Jan 2010. The chapter is organized by specific stem cell technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. A comprehensive series of appendices is provided organized by stem cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. The report also includes numerous tables and figures that illustrate the trends and activities in stem cell partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of stem cell technologies and products. Key benefits Global Stem Cell Partnering Terms and Agreements 2010-2023 provides the reader with the following key benefits: In-depth understanding of stem cell deal trends since 2010 Access to headline, upfront, milestone and royalty data Detailed access to actual stem cell contracts entered into by leading biopharma companies Identify most active stem cell dealmakers since 2010 Insight into terms included in a stem cell partnering agreement, with real world examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Report scope Global Stem Cell Partnering Terms and Agreements 2010-2023 is intended to provide the reader with an in-depth understanding and access to stem cell trends and structure of deals entered into by leading companies worldwide. Stem Cell Partnering Terms and Agreements includes: Trends in stem cell dealmaking in the biopharma industry since 2010 Access to headline, upfront, milestone and royalty data Access to stem cell contract documents Leading stem cell deals by value since 2010 Most active stem cell dealmakers since 2010 In Global Stem Cell Partnering Terms and Agreements 2010-2023, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Technology type Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Global Stem Cell PartneringTerms and Agreements 2010-2023 report provides comprehensive access to available deals and contract documents for over 700 stem cell deals. Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Companies Mentioned Regenetech Regeneus Stempeutics Bakulev Center of Cardiovascular Surgery of Russian Academy of Sciences CNA Development The New York Stem Cell Foundation Arthrex Generex Biotechnology Celltex Therapeutics Viscofan BioEngineering Dana-Farber Cancer Institute Biosafe BioLife Solutions Rockefeller University Montefiore Medical Center Wake Forest University Fast Forward Jain Foundation Promega Lineage Cell Therapeutics Hepregen Histogen Lentigen Philogen Vascugen Shenogen Pharma VistaGen Therapeutics Centogene Spinogenix Transgenomic Biological Industries Procognia Apceth Munich Technical University Lehigh University Monash University Abu Dhabi Stem Cells Center Shanghai Cell Therapy Group Shanghai Jia Fu Medical Apparatus Sinopharm AXM Pharma For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Bordeaux, France / October 11th, 2022 – TreeFrog Therapeutics, a biotechnology company developing stem cell-derived therapies in regenerative medicine and immuno-oncology based on the biomimetic C-Stem™ technology platform, and Invetech, a global leader in the development and production of automated manufacturing solutions for cell and advanced therapies, today announced the delivery of a GMP-grade cell encapsulation device using the C-Stem™ technology. The machine will be transferred in 2023 to a contract development and manufacturing organization (CDMO) to produce TreeFrog’s cell therapy candidate for Parkinson’s disease, with the aim of a first-in-human trial in 2024. Over 2023, Invetech will deliver three additional GMP encapsulation devices to support TreeFrog’s in-house and partnered cell therapy programs in regenerative medicine and immuno-oncology. Blending microfluidics and stem cell biology, TreeFrog’s C-Stem™ technology generates alginate capsules seeded with induced pluripotent stem cells (iPSCs) at very high speed. Engineered to mimic the in vivo stem cell niche, the capsules allow iPSCs to grow exponentially in 3D, and to differentiate into ready-to-transplant functional microtissues. And because alginate is both porous and highly resistant, encapsulated iPSCs can be expanded and differentiated in large-scale bioreactors without suffering from impeller-induced shear stress. “TreeFrog Therapeutics introduces a breakthrough technology for cell therapy, which impacts scale, quality, as well as the efficacy and safety potential of cellular products. Automating this disruptive technology and turning it into a robust GMP-grade instrument is a tremendous achievement for our team. This deliverable is the result of a very fruitful and demanding collaboration with TreeFrog’s engineers in biophysics and bioproduction over the past four years. We’re now eager to learn how the neural microtissues produced with C-Stem™ will perform in the clinic.” Anthony Annibale, Global VP Commercial at Invetech. Started in 2019, the collaboration between TreeFrog and Invetech led to the delivery of a prototype in October 2020. With this research-grade machine, TreeFrog demonstrated the scalability of C-Stem™, moving within six months from milliliter-scale to 10-liter bioreactors. In June 2021, the company announced the production of two single-batches of 15 billion iPSCs in 10L bioreactors with an unprecedented 275-fold amplification per week, striking reproducibility and best-in-class cell quality. The new GMP-grade device delivered by Invetech features the same technical specifications. The machine generates over 1,000 capsules per second, allowing to seed bioreactors from 200mL to 10L. However, the device was entirely redesigned to fit bioproduction standards. “With the GMP device, our main challenge was to minimize the learning curve for operators, so as to facilitate tech transfer. Invetech and our team did an outstanding job in terms of automation and industrial design to make the device both robust and easy to use. As an inventor, I am so proud of the journey of the C-Stem™ technology. Many elements have been changed and improved on the way, and now comes the time to put the platform in the hands of real-world users to make real products.” Kevin Alessandri, Ph.D., co-founder and chief technology officer, TreeFrog Therapeutics “In October 2020, we announced that we were planning for the delivery of a GMP encapsulation device by the end of 2022. Exactly two years after, we’re right on time. I guess this machine testifies to the outstanding execution capacity of TreeFrog and Invetech. But more importantly, this machine constitutes a key milestone. Our platform can now be used to manufacture clinical-grade cell therapy products. Our plan is to accelerate the translation of our in-house and partnered programs to the clinic, with a focus on immuno-oncology and regenerative medicine applications.” Frederic Desdouits, Ph.D., chief executive officer, TreeFrog Therapeutics About Invetech For pathfinders in cell and gene therapy striving to accelerate next-generation care, Invetech delivers robust, scalable and cost-effective manufacturing systems for clinical through to high-volume commercial production. Since 2003, Invetech’s Cell Therapy Group has provided Assured Pathways™ to the commercial manufacturing of cell, gene and tissue therapies, including peripheral and precursor materials such as viral vector and media. Invetech configures manufacturing systems to address client process demands, building from portfolio of proven modules and platform technology. Invetech is a globally recognized leader in life science automation, and a member of the Fortive (NYSE: FTV) group of companies. invetechgroup.com About TreeFrog Therapeutics TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. Bringing together over 100 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M over the past 3 years to advance a pipeline of stem cell-based therapies in immuno-oncology and regenerative medicine. In 2022, the company opened technological hubs in Boston, USA, and Kobe, Japan, with the aim of driving the adoption of the C-StemTM platform and establish strategic alliances with leading academic, biotech and industry players in the field of cell therapy. Media Contact Pierre-Emmanuel Gaultier TreeFrog Therapeutics + 33 6 45 77 42 58 pierre@treefrog.fr